OMT announces a breakthrough in the development of a novel human antibody platform
Researchers at OMT successfully created heritable, specific and permanent genetic modifications in rats using Zinc Finger Nuclease (ZFN) technology. This achievement paves the way for unrestricted development of a novel human monoclonal antibody platform.